GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tevogen Bio Holdings
Shares of Tevogen, a biotech company working in cell therapy, reflect high speculative interest in its platform. The price trajectory depends not on revenue, but on news of clinical trials and investor confidence in the breakthrough potential of its technology.
Share prices of companies in the market segment - Neuro
Tevogen Bio develops T-cell therapies for viral infections and cancer, striving to create affordable and effective treatments. We classify it in the Neuroscience segment, although its technologies are broader and encompass immuno-oncology. The chart below illustrates the dynamics of this disruptive, yet high-risk, biotech sector.
Broad Market Index - GURU.Markets
Tevogen Bio is a biopharmaceutical company developing T-cell-based cell therapies for the treatment of viral infections and cancer. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
TVGN - Daily change in the company's share price Tevogen Bio Holdings
Shares of Tevogen Bio, a biotech company, exhibit high volatility, as measured by change_co. This indicator reflects sensitivity to news about clinical trials. This metric is important for analyzing the innovative biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Tevogen Bio Holdings Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with the performance of TVGN, which focuses on cell therapy, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tevogen Bio is a biotech company developing cell therapies for the treatment of viral infections and cancer. Its shares are a bet on scientific breakthroughs in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovation market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tevogen Bio Holdings
Tevogen Bio Holdings' year-to-date performance is a story of developing a new generation of cell therapy. Its 12-month market cap depends entirely on progress in clinical trials of its T-cell platforms for the treatment of viral infections and cancer. Success could lead to a breakthrough, offering more affordable and effective therapy.
Annual dynamics of market capitalization of the market segment - Neuro
Tevogen, an early-stage biotech company, is developing cell therapies. Its performance is completely separate from the sector and depends on news of clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique scientific developments in neuroscience.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tevogen is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tevogen Bio Holdings
Tevogen Bio Holdings (Neuro)'s market value is driven by biotech operating cycles: news about clinical trials (especially Phase II/III), partnerships, and potential regulatory approvals for neurological and other disease therapies, which causes sharp monthly fluctuations in the Perf_Month_Co chart.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the volatile biotech sector. For Tevogen, an early-stage company, it's the backdrop. Its movements demonstrate how investor expectations surrounding breakthroughs in cell therapy and overall market sentiment influence the entire industry, against which the company is developing its platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tevogen Bio is a clinical-stage biotech company developing T-cell therapies for the treatment of viral infections and cancer. Its value depends almost entirely on the results of clinical trials. The overall market has little impact on Tevogen; its shares are driven by scientific news, which can cause explosive gains or losses on any given day.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tevogen Bio Holdings
Tevogen Bio is a clinical-stage biopharmaceutical company developing T-cell-based cell therapies for the treatment of viral infections and cancer. Its weekly stock price is highly volatile, driven by clinical trial news.
Weekly dynamics of market capitalization of the market segment - Neuro
Tevogen Bio is developing T-cell-based cell therapy. This is a cutting-edge but high-risk area of biotechnology. The company's stock price fluctuates based on clinical trial news. The chart clearly shows how out of sync its performance is with overall healthcare trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tevogen is a biotech company whose shares are driven by news of clinical trials. It's a classic example of an asset that doesn't correlate with the market. The chart clearly demonstrates how much its performance is driven by scientific news rather than general economic trends.
Market capitalization of the company, segment and market as a whole
TVGN - Market capitalization of the company Tevogen Bio Holdings
Tevogen Bio's market capitalization reflects investors' faith in its platform for developing personalized T-cell therapy. As an early-stage company, its valuation is speculative and based on the potential of its technology for treating cancer and viral infections. It's a high-risk bet on cutting-edge science.
TVGN - Share of the company's market capitalization Tevogen Bio Holdings within the market segment - Neuro
Tevogen Bio is a clinical-stage biotech company developing a platform for creating T-cell therapies for the treatment of viral infections and cancer. Its market share reflects its potential. The graph is a venture bet that its innovative approach will lead to the creation of effective drugs.
Market capitalization of the market segment - Neuro
The chart below shows the overall value of the biotech sector. Tevogen Bio is a company at the forefront of cell therapy. Its platform enables the creation of "on-demand" drugs from T cells to combat viruses and cancer. The potential of this market is enormous, and Tevogen is striving to prove that its unique approach can become a new standard of care.
Market capitalization of all companies included in a broad market index - GURU.Markets
Tevogen Bio is a biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. Its market capitalization reflects its scientific platform. The chart below shows the economic weight of the advanced cell therapy sector.
Book value capitalization of the company, segment and market as a whole
TVGN - Book value capitalization of the company Tevogen Bio Holdings
Tevogen Bio's book value is derived from its intellectual property in its platform for developing T-cell therapies for viral infections and cancer, as well as the capital for its development. The graph represents the financial starting point for the biotech company, which is investing in its unique approach to creating "on-demand" drugs from a patient's own cells.
TVGN - Share of the company's book capitalization Tevogen Bio Holdings within the market segment - Neuro
Tevogen Bio develops cell therapies. The chart shows its share of actual R&D assets. These are its laboratories where a platform for producing T-cells capable of fighting viruses and cancer is being created, offering hope to many patients.
Market segment balance sheet capitalization - Neuro
Tevogen Bio is a biotech company whose value is locked into its scientific platform. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which highlights its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Tevogen Bio develops T-cell-based cell therapy for the treatment of viruses and cancer. The company's assets are its scientific platform. A modest stake in BCap_All provides the material basis for the creation of "living drugs" that could offer a new approach to combating serious diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tevogen Bio Holdings
Tevogen Bio is a biotech company. Its entire market capitalization is a premium to its cash flow. This premium is a bet on its platform for developing T-cell therapies for the treatment of viruses and cancer.
Market to book capitalization ratio in a market segment - Neuro
Tevogen Bio is a biotech company developing cell therapies. Its value is based almost entirely on its scientific potential. The chart shows the huge premium to book value that investors are paying for the hope of developing breakthrough treatments for viruses and cancer.
Market to book capitalization ratio for the market as a whole
Tevogen Bio is developing next-generation cell therapy. Its entire value lies in its scientific platform and the hope for future cures for cancer and viral infections. This chart shows the extreme premium investors are willing to pay for this potentially revolutionary technology, ignoring traditional tangible assets.
Debts of the company, segment and market as a whole
TVGN - Company debts Tevogen Bio Holdings
Tevogen Bio, a biotech company developing T-cell-based cell therapies, is raising capital to fund its innovative research. The debt burden reflects the high costs of platform development and clinical trials required to bring the next generation of cancer and viral infection treatments to market.
Market segment debts - Neuro
Tevogen Bio is a clinical-stage biotech company developing T-cell-based cell therapies for the treatment of viruses and cancer. This cutting-edge technology requires significant funding. This chart shows whether the company is pursuing the traditional biotech equity funding model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tevogen Bio Holdings
Tevogen Bio develops cell therapy. This is one of the most advanced and capital-intensive areas of biotechnology, where the journey from lab to patient takes years and costs hundreds of millions. This chart shows the company's reliance on debt to fund its research, which is the main financial risk for investors.
Market segment debt to market segment book capitalization - Neuro
Tevogen Bio develops T-cell therapy for viral infections and cancer. This chart shows debt trends in the biotech sector. For a company in clinical trials, this allows them to assess how they finance their innovative but expensive research and how their financial model compares to other players at the forefront of science.
Debt to book value of all companies in the market
Tevogen Bio develops T-cell therapy for the treatment of viral infections and cancer. Like most research-stage biotech companies, Tevogen relies entirely on equity capital to fund its research. This chart, showing the debt ratio in the economy, clearly demonstrates how the company's financial model differs from traditional sectors and carries different risks.
P/E of the company, segment and market as a whole
P/E - Tevogen Bio Holdings
Tevogen Bio is a biopharmaceutical company developing T-cell-based cell therapies for the treatment of viral infections and cancer. This chart reflects investors' confidence in the potential of its scientific platform. The valuation is not based on current revenue but rather on the future success of its innovative treatments.
P/E of the market segment - Neuro
This industry chart for biotech companies provides key context for Tevogen Bio. It reflects generally high valuations based on breakthrough hopes. Comparisons with it help understand whether Tevogen's unique platform for developing T-cell therapies for viruses and cancer is considered more promising than those of dozens of other biotechs.
P/E of the market as a whole
Tevogen Bio is developing T-cell-based cell therapy for the treatment of viral infections and cancer. This cutting-edge technology has yet to be commercially proven. This chart of overall biotech risk appetite shows whether investors are willing to fund such science-intensive platforms, which promise to treat a wide range of diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tevogen Bio Holdings
Tevogen Bio is a clinical-stage biotech company developing T-cell-based therapies for the treatment of viral infections and cancer. This chart shows the speculative expectations for its platform. The valuation depends entirely on the results of clinical trials and investor confidence in the potential of its technology to create "off-the-shelf" cell-based therapies.
%20P%2FE%20Tevogen%20Bio%20Holdings&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tevogen-Bio-Holdings&v=1772513871179 "Chart of the company's future (projected) P/E Tevogen Bio Holdings")
Future (projected) P/E of the market segment - Neuro
Tevogen Bio develops T-cell therapies for the treatment of viral infections and cancer. This chart reflects investor expectations for the company's profitability relative to the sector. It provides insight into the market's confidence in its scientific platform and potential for developing new immune cell-based therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513871180 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Tevogen Bio is a clinical-stage biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. For a company operating at the cutting edge of science, this market risk appetite curve is vital. Funding for breakthrough but capital-intensive research directly depends on investors' willingness to invest in long-term projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513871248 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tevogen Bio Holdings
Tevogen Bio is a biotech company developing a platform for creating T-cell therapies for the treatment of viral infections and cancer. This chart shows the company's financial performance at the clinical trial stage, where it is at the forefront of cellular immunotherapy.
Profit of companies in the market segment - Neuro
Tevogen Bio develops T-cell-based cell therapies for the treatment of viral infections and cancer. This chart shows profitability in the neuroscience and oncology sectors. For TVGN, this reflects the hopes associated with their innovative platform, which could offer treatments for a wide range of diseases in which the immune system plays a key role.
Overall market profit
Tevogen Bio is a clinical-stage biotechnology company developing a platform for T-cell therapy against viral infections and cancer. This is cutting-edge science, and the company's future depends on its research. The general economic trends reflected in this chart do not directly impact its scientific progress.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tevogen Bio Holdings
Tevogen Bio is a clinical-stage biotechnology company developing a platform for the creation of T-cell therapies for the treatment of viral infections and cancer. The revenue projections presented here are speculative and reflect expectations for the success of its innovative approach in clinical trials.
%20profit%20of%20the%20company%20Tevogen%20Bio%20Holdings&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tevogen-Bio-Holdings&v=1772513871510 "Graph of future (projected) profit of the company Tevogen Bio Holdings")
Future (predicted) profit of companies in the market segment - Neuro
Tevogen Bio Holdings develops T-cell-based cell therapy for the treatment of viral infections and cancer. The revenue forecast for this cutting-edge segment depends on the success of clinical trials. This chart reflects analysts' belief that T-cell therapy has the potential to become an effective tool not only in oncology but also in the fight against severe infections.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513871546 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Tevogen Bio develops cell therapies for the treatment of viral infections and cancer. As a clinical-stage company, it depends on successful research and raising capital. The market profit forecasts shown here reflect the overall risk appetite of investors, which is critical for funding such biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513871571 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tevogen Bio Holdings
Tevogen Bio is a biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. This chart shows a high speculative valuation. Investors are betting on its innovative platform and potential to create drugs to combat serious diseases, assessing its future prospects.
P/S market segment - Neuro
Tevogen Bio develops T-cell therapies for the treatment of viral infections and cancer. Its platform enables the creation of specific T-cells to combat various diseases. This chart shows the average revenue estimate in the biotech sector, which helps us understand the high expectations investors have for Tevogen's scientific platform.
P/S of the market as a whole
Tevogen Bio is a biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. The company is in clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tevogen Bio Holdings
Tevogen Bio is developing T-cell-based cell therapy for the treatment of viral infections and cancer. This chart shows how the market values the company based on its future revenue potential. It reflects expectations for the success of its innovative platform for creating "off-the-shelf" cell products.
%20P%2FS%20Tevogen%20Bio%20Holdings&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tevogen-Bio-Holdings&v=1772513871655 "The graph of the company's future (projected) P/S Tevogen Bio Holdings")
Future (projected) P/S of the market segment - Neuro
Tevogen Bio develops T-cell-based cell therapies for the treatment of viral infections and cancer. Its platform aims to create affordable treatments. This chart reflects investors' confidence in its scientific approach and the potential of its developments to address serious healthcare challenges.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513871709 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Tevogen Bio is developing T-cell therapy for the treatment of viral infections and cancer. As a clinical-stage company, it is entirely dependent on funding. This market optimism curve is critical for Tevogen. Investors' appetite for high-risk biotech projects, which are crucial for their survival, is directly linked to their belief in overall economic growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513871752 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tevogen Bio Holdings
Tevogen Bio is a clinical-stage biotechnology company developing innovative T-cell-based cell therapies for the treatment of viral infections and cancer. The company currently has no commercial products. This timeline will show whether its unique platform can lead to the development of effective and commercially successful drugs.
Sales of companies in the market segment - Neuro
Tevogen Bio is a clinical-stage biotechnology company developing a platform for the creation of T-cell therapies for the treatment of viral infections, cancer, and neurological diseases. Their goal is to create affordable and effective "drugs on demand." Currently, the company has no commercial revenue, focusing on clinical trials.
Overall market sales
Tevogen Bio is a biotechnology company developing a platform for creating T-cell-based cell therapies for the treatment of viral infections and cancer. Its approach is aimed at creating affordable and effective treatments. This total revenue chart includes the healthcare sector, where TVGN works on innovative therapeutic solutions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tevogen Bio Holdings
Tevogen Bio is developing T-cell-based cell therapy for the treatment of viral infections and cancer. Its uniqueness lies in its ability to simultaneously target multiple targets. This graph reflects analysts' confidence in the potential of this innovative platform and its ability to create effective treatments.
%20sales%20of%20the%20company%20Tevogen%20Bio%20Holdings&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tevogen-Bio-Holdings&v=1772513871826 "Schedule of future (projected) sales of the company Tevogen Bio Holdings")
Future (projected) sales of companies in the market segment - Neuro
Tevogen Bio is a clinical-stage biotechnology company developing T-cell-based cell therapies for the treatment of viral infections and cancer. This chart shows forecasts for the advanced cell therapy market. It reflects expectations for the development of this revolutionary treatment approach, where Tevogen aims to carve out a niche with its unique platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513871843 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Tevogen Bio, a biotech company developing cell therapies, sees this chart as a reflection of the investment climate in knowledge-intensive industries. The stable economic growth projected here provides the capital needed to conduct clinical trials and bring innovative treatments for viral infections and cancer to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513871863 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tevogen Bio Holdings
Tevogen Bio is a clinical-stage biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. Its financial performance reflects its high R&D expenditures. This chart illustrates the level of investment in its scientific platform, which is typical for companies seeking to develop breakthrough treatments.
Market segment marginality - Neuro
Tevogen Bio is developing T-cell-based cell therapies for the treatment of viral infections and cancer. This graph reflects the potential of its unique scientific platform. Future high operating revenue will demonstrate that its technology can offer effective and affordable treatments.
Market marginality as a whole
Tevogen Bio is a clinical-stage biotechnology company developing cell therapies. Its value and prospects depend entirely on the results of clinical trials. This total market return chart bears no relation to Tevogen's scientific trajectory, which is determined by data and regulatory decisions.
Employees in the company, segment and market as a whole
Number of employees in the company Tevogen Bio Holdings
Tevogen Bio is a clinical-stage biotechnology company developing a platform for next-generation T-cell therapies targeting viral infections and cancer. This graph shows the team's efforts to create a "ready-to-use" cell therapy that will be more accessible than existing personalized treatments.
Share of the company's employees Tevogen Bio Holdings within the market segment - Neuro
Tevogen Bio is a biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. This cutting-edge science requires the best immunologists and cell engineers. This graph illustrates the concentration of unique talent needed to create the next generation of medicines.
Number of employees in the market segment - Neuro
Tevogen Bio is a biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. This graphic shows a team of scientists working on creating "living drugs" using a patient's own immune cells to fight disease. This is one of the most advanced areas of modern medicine.
Number of employees in the market as a whole
Tevogen Bio Holdings develops cell therapies for the treatment of viral infections and cancer. Their research-intensive business requires significant investment. The overall economic situation, reflected in the employment chart, creates a favorable environment for raising capital. Market stability increases investor willingness to invest in long-term biotech projects like Tevogen's.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tevogen Bio Holdings (TVGN)
Tevogen Bio Holdings is a clinical-stage biotech company developing cell therapies. This chart is a measure of their hopes. Their astronomical market capitalization per employee demonstrates that investors believe in their scientific platform. The company's value reflects the potential for future drugs being developed by a small team of highly skilled scientists.
%20of%20the%20company%20Tevogen%20Bio%20Holdings%20(TVGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tevogen-Bio-Holdings-TVGN&v=1772513872096 "Chart of market capitalization per employee (in thousands of dollars) of the company Tevogen Bio Holdings (TVGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Tevogen Bio is developing T-cell therapy for viral infections and cancer. For a development-stage biotech, a high valuation per employee reflects investors' confidence in its scientific platform. This chart shows the market valuation of its potential based on its small but highly qualified team of scientists.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513872159 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Tevogen Bio is a biotech company developing T-cell-based cell therapies for the treatment of viral infections and cancer. In this cutting-edge field, this statistic reflects its enormous scientific potential. The high valuation per employee reflects investors' belief that its platform can lead to breakthrough treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513872180 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tevogen Bio Holdings (TVGN)
Tevogen Bio is a clinical-stage biotech company developing T-cell therapies for cancer and viruses. This graph is negative. The company has no revenue. Its entire scientific staff is dedicated to conducting expensive clinical trials. Each employee is an investment in technology that, if successful, will generate future revenue.
%20Chart%20Tevogen%20Bio%20Holdings%20(TVGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tevogen-Bio-Holdings-TVGN&v=1772513872207 "Company Profit Per Employee (in thousands of dollars) Chart Tevogen Bio Holdings (TVGN)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Tevogen Bio Holdings is a clinical-stage biotech company developing a T-cell therapy platform (TVGN) for the treatment of viral infections, neurological diseases, and cancer. This chart represents an industry benchmark. It serves as a benchmark for biotech R&D, demonstrating the potential profitability the sector is aiming for if their innovative cell platform is successful.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513872275 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Tevogen Bio is a clinical-stage biotech company developing a T-cell therapy platform for the treatment of viral infections and cancer. This is R&D. The chart shows the R&D investment (negative return) per scientist working on this complex cell platform in the hopes of creating a breakthrough drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513872300 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tevogen Bio Holdings (TVGN)
Tevogen Bio is developing T-cell-based cell therapies for the treatment of viral infections and cancer. This graph reflects the early stages of biotech development. In the future, if its platform proves successful, a sharp increase in revenue per employee will demonstrate the enormous value of its innovative approach to creating "drugs on demand."
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tevogen-Bio-Holdings-TVGN&v=1772513872390 "Sales chart per company employee Tevogen Bio Holdings (TVGN)")
Sales per employee in the market segment - Neuro
Tevogen Bio (TVGN) is a clinical-stage biotech developing cell therapies (T-cells) for the treatment of cancer and viral infections. They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average.
Sales per employee for the market as a whole
Tevogen Bio is a clinical-stage biotech company developing a T-cell therapy platform for the treatment of viral infections and cancer. This is a pure R&D operation. This graph will likely show zero revenue, as their team of scientists does not yet have a commercial product on the market.
Short shares by company, segment and market as a whole
Shares shorted by company Tevogen Bio Holdings (TVGN)
Tevogen Bio (TVGN) is a clinical-stage biotech developing a T-cell therapy platform for the treatment of viral infections and cancer. This chart measures bearish bets. The high short interest in TVGN reflects deep investor skepticism about its scientific platform, massive operating losses, and the risks associated with the highly competitive cell therapy field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tevogen-Bio-Holdings-TVGN&v=1772513872640 "Short Shares Chart for the Company Tevogen Bio Holdings (TVGN)")
Shares shorted by market segment - Neuro
Tevogen Bio (TVGN) is a biotech company developing cell therapy (T-cells) for the treatment of viral infections and cancer. This chart illustrates the general skepticism in the cell therapy sector, reflecting investor doubts about the success of clinical trials and the intense competition in this field.
Shares shorted by the overall market
Tevogen Bio (TVGN) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing that TVGN will be unable to raise funds to continue R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tevogen Bio Holdings (TVGN)
Tevogen Bio is a clinical-stage biotech company working in T-cell therapy. This chart measures pure speculative hope. It shows when the stock is "overbought" on the slightest positive signal from the lab or "oversold" amid a long R&D cycle.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tevogen-Bio-Holdings-TVGN&v=1772513872791 "RSI 14 indicator chart for the company's stock Tevogen Bio Holdings (TVGN)")
RSI 14 Market Segment - Neuro
Tevogen Bio is a clinical-stage biopharmaceutical company developing a T-cell therapy platform (TVGN 489) for the treatment of viral infections, cancer, and neurological diseases. This chart reflects overall sentiment in the biotech sector, helping to assess how the market views this speculative cell therapy industry.
RSI 14 for the overall market
Tevogen Bio (TVGN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TVGN (Tevogen Bio Holdings)
Tevogen Bio (TVGN) is a clinical-stage biotech developing cell therapies (T-cells) for the treatment of cancer and viral infections. This chart shows the average target price. It reflects analysts' speculative assessment of the potential of this innovative scientific platform and early trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TVGN-Tevogen-Bio-Holdings&v=1772513872838 "A chart showing analyst consensus forecasts for the expected stock price. TVGN (Tevogen Bio Holdings)")
The difference between the consensus estimate and the actual stock price TVGN (Tevogen Bio Holdings)
Tevogen Bio is a biotech company developing next-generation T-cell therapies for the treatment of cancer, viruses, and neurological diseases. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the breakthrough potential of this scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TVGN-Tevogen-Bio-Holdings&v=1772513872886 "A chart showing the difference between the consensus forecast and the actual stock price. TVGN (Tevogen Bio Holdings)")
Analyst consensus forecast for stock prices by market segment - Neuro
Tevogen Bio is a clinical-stage biotech company developing cell therapies to combat cancer and viral infections. This chart shows analysts' overall expectations for the entire neuroscience and immunology sector. It's critically important because it reflects the overall investor sentiment: whether they are willing to fund risky R&D projects or whether the sector has entered a "biotech winter."
Analysts' consensus forecast for the overall market share price
Tevogen Bio is a clinical-stage biotech company developing a T-cell therapy platform for the treatment of cancer, viruses, and neurological diseases. This is cutting-edge science. This chart shows overall market sentiment. For Tevogen, as an R&D startup, it's important to understand how the overall risk appetite (sentiment) impacts their ability to fund R&D. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tevogen Bio Holdings
Tevogen Bio is a clinical-stage biotech company developing a platform for creating T-cell therapies (immunotherapy). They are targeting viral infections, cancer, and neurological diseases. This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative assessment of their R&D progress and the potential of their innovative cell platform.
AKIMA Market Segment Index - Neuro
Tevogen Bio is a clinical-stage biotech company developing cell therapy (T-cells) for the treatment of cancer and viral infections. This chart shows the average index for the neuroscience segment. It provides a benchmark for how Tevogen's performance compares to the sector average among companies pursuing scientific breakthroughs.
The AKIM Index for the overall market
Tevogen Bio is a biotech company specializing in T-cell immunotherapy for the treatment of viral infections and cancer. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this early-stage scientific platform.
